Savas Celebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Savas Celebi has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Sinan Aydogdu
Yuksek Ihtisas Training and Research Hospital Ankara, Ankara, Turkey
11 shared publicationsBerkten Berkalp
Department of Cardiology, TOBB Economics and Technology University Medical School, Ankara, Turkey
7 shared publicationsOzlem Ozcan Celebi
Yuksek Ihtisas Training and Research Hospital Ankara, Ankara, Turkey
7 shared publications- Ozlem Ozcan Celebi
Ankara Bilkent City Hospital
7 shared publications Basri Amasyali
Department of Cardiology, TOBB Economics and Technology University Medical School, Ankara, Turkey
5 shared publicationsErdem Diker
Department of Cardiology, TOBB Economics and Technology University Medical School, Ankara, Turkey
5 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (5) , 261-264
Caval Valve Implantation Procedure in 7 Cases of Torrential Tricuspid Regurgitation and Step-by-Step Description of the Procedure
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (5) , 261-264
Open AccessCaval Valve Implantation Procedure in 7 Cases of Torrential Tricuspid Regurgitation and Step-by-Step Description of the Procedure
- 3 January 2024
- Published by Springer Nature in Health Care Analysis
- Vol. 34 (3) , 1-21
A Qualitative Research Survey on Cardiologist’s Ethical Stance in Cases of Moral Dilemmas in Cardiology Clinics
This study sought to determine cardiologists’ degrees of ethical awareness and preferred courses of action for ethical dilemmas frequently encountered in clinical settings. For this evaluation, an online survey was created and sent to cardiologists affiliated with various academic posts in Ankara, Turkey. The survey included ten cases with various ethical considerations selected from our book, “Clinic Ethics with Cases from Cardiology.” Four possible action choices were defined for each case. Participants were asked to choose one or more of these preferences. In addition, a fictional change was made in each case’s context without changing the original ethical issue, and participants were asked whether an attitude different from the first chosen one was preferred. The participation ratio was 49/185 (26%), consent ratio 47/185 (25,4%), and completion ratio 44/185 (23,7%). Nine of the ten scenario changes did not change participants’ preferred action. For most questions, action preferences were concentrated between the two options. Although legal regulations did not reduce ethical dilemmas, they clarified physicians’ action preferences. Similarly, as an obscure moral issue gained prominence, physicians were forced to draw clearer lines in their actions. External factors such as healthcare emergencies can change physicians’ ethical dilemma-solving attitudes.
- 3 January 2024
- Published by Springer Nature in Health Care Analysis
- Vol. 34 (3) , 1-21
A Qualitative Research Survey on Cardiologist’s Ethical Stance in Cases of Moral Dilemmas in Cardiology Clinics
This study sought to determine cardiologists’ degrees of ethical awareness and preferred courses of action for ethical dilemmas frequently encountered in clinical settings. For this evaluation, an online survey was created and sent to cardiologists affiliated with various academic posts in Ankara, Turkey. The survey included ten cases with various ethical considerations selected from our book, “Clinic Ethics with Cases from Cardiology.” Four possible action choices were defined for each case. Participants were asked to choose one or more of these preferences. In addition, a fictional change was made in each case’s context without changing the original ethical issue, and participants were asked whether an attitude different from the first chosen one was preferred. The participation ratio was 49/185 (26%), consent ratio 47/185 (25,4%), and completion ratio 44/185 (23,7%). Nine of the ten scenario changes did not change participants’ preferred action. For most questions, action preferences were concentrated between the two options. Although legal regulations did not reduce ethical dilemmas, they clarified physicians’ action preferences. Similarly, as an obscure moral issue gained prominence, physicians were forced to draw clearer lines in their actions. External factors such as healthcare emergencies can change physicians’ ethical dilemma-solving attitudes.
- 1 September 2023
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in e-Journal of Cardiovascular Medicine
- Vol. 11 (3) , 123-126
Successful Balloon Valvuloplasty in a Patient with Severe Bioprosthetic Tricuspid Valve Stenosis: Case Report
- 1 September 2023
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in e-Journal of Cardiovascular Medicine
- Vol. 11 (3) , 123-126
Successful Balloon Valvuloplasty in a Patient with Severe Bioprosthetic Tricuspid Valve Stenosis: Case Report
- Open Access
- 13 September 2021
- Published by Wiley in Developing World Bioethics
- Vol. 22 (4) , 217-230
Comparison of COVID‐19 studies registered in the clinical trial platforms: A research ethics analysis perspective
Background: The coronavirus disease (COVID‐19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk‐benefit analysis may occasionally face challenges owing to the time limitations in the pandemic.Methodology: This study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID‐19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site‐, design‐, and participant‐related issues. The discussion is based on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health.Results: There were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design‐related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information.Conclusion: With this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms.
- 13 September 2021
- Published by Wiley in Developing World Bioethics
- Vol. 22 (4) , 217-230
Open AccessComparison of COVID‐19 studies registered in the clinical trial platforms: A research ethics analysis perspective
Background: The coronavirus disease (COVID‐19) treatment must be based on scientific methods such as clinical trials. Trials involving human subjects and those requiring a risk‐benefit analysis may occasionally face challenges owing to the time limitations in the pandemic.Methodology: This study analyses the WHO's International Clinical Trials Registry Platform and clinicaltrials.gov, where most COVID‐19 clinical trials are registered, according to ethical criteria including study design, conflicts of interest, enrollment of healthcare workers, study locations, site‐, design‐, and participant‐related issues. The discussion is based on three aspects: the quality of the information to be produced, the relevance to significant health problems, and the creation or evaluation of interventions, policies, or practices that promote individual or public health.Results: There were significant differences between the two platforms regarding the investigational medicinal product (IMP), the comparator, ethics committee/institutional review board approval, plan to share individual participant data, study phase, site, IMP, and design‐related issues. Conflict of interest, sponsor information, and management of vulnerable groups were the main areas wherein both platforms lacked sufficient information.Conclusion: With this analysis, we aimed to define a minimum set of ethical criteria for clinical trial platforms to obtain standardization between these two platforms.
- Open Access
- 3 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (11) , 4226-4234
Remote patient monitoring after cardiac surgery: The utility of a novel telemedicine system
Objective We examined cardiac surgery patients who underwent monitoring of postoperative vital parameters using medical monitoring devices which transferred data to a mobile application and a web-based software. Methods From November 2017 to November 2020, a total of 2340 patients were enrolled in the remote patient monitoring system after undergoing cardiac surgery. The medical devices recorded vital parameters, such as blood pressure, pulse rate, saturation, body temperature, blood glucose, and electrocardiography were measured via the Health Monitor DakikApp and Holter ECG DakikApp devices which reported data to web-based software and a mobile application (DakikApp Mobile Systems, Remscheid, Germany). During the follow-up period, patients were contacted daily through text and voice messages, and video conferences. Remote Medical Evaluations (RMEs) concerning patients' medical states were performed. Medication reminders, daily treatment were communicated to the patients with the DakikApp Mobile Systems Software. Results During a mean follow-up period of 78.9 ± 107.1 (10–395) days, a total of 135,786 patient contacts were recorded (782 video conferences, 2805 voice messaging, and 132,199 text correspondence). The number of RMEs handled by the Telemedicine Team was 79,560. A total of 105,335 vital parameter measurements were performed and 5024 hospital application requests (6.3% per RME) were addressed successfully and hospitalization was avoided. A total of 144 (6.1%) potentially life-threatening complications were found to have been diagnosed early using the Telemedicine System. Conclusion Remote Patient Monitoring Systems combined with professional medical devices are feasible, effective, and safe for the purpose of improving postoperative outcomes.
- 3 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (11) , 4226-4234
Open AccessRemote patient monitoring after cardiac surgery: The utility of a novel telemedicine system
Objective We examined cardiac surgery patients who underwent monitoring of postoperative vital parameters using medical monitoring devices which transferred data to a mobile application and a web-based software. Methods From November 2017 to November 2020, a total of 2340 patients were enrolled in the remote patient monitoring system after undergoing cardiac surgery. The medical devices recorded vital parameters, such as blood pressure, pulse rate, saturation, body temperature, blood glucose, and electrocardiography were measured via the Health Monitor DakikApp and Holter ECG DakikApp devices which reported data to web-based software and a mobile application (DakikApp Mobile Systems, Remscheid, Germany). During the follow-up period, patients were contacted daily through text and voice messages, and video conferences. Remote Medical Evaluations (RMEs) concerning patients' medical states were performed. Medication reminders, daily treatment were communicated to the patients with the DakikApp Mobile Systems Software. Results During a mean follow-up period of 78.9 ± 107.1 (10–395) days, a total of 135,786 patient contacts were recorded (782 video conferences, 2805 voice messaging, and 132,199 text correspondence). The number of RMEs handled by the Telemedicine Team was 79,560. A total of 105,335 vital parameter measurements were performed and 5024 hospital application requests (6.3% per RME) were addressed successfully and hospitalization was avoided. A total of 144 (6.1%) potentially life-threatening complications were found to have been diagnosed early using the Telemedicine System. Conclusion Remote Patient Monitoring Systems combined with professional medical devices are feasible, effective, and safe for the purpose of improving postoperative outcomes.
- 22 May 2020
- Published by Wiley in International Wound Journal
- Vol. 17 (5) , 1346-1355
The association between thrombotic and inflammatory biomarkers and lower‐extremity peripheral artery disease
Lower‐extremity peripheral artery disease (LEAD) is associated with increased rates of mortality and morbidity. The aim of this study was to evaluate the associations among inflammatory and thrombotic markers and lower‐extremity peripheral disease. A total of 280 patients were enrolled in this study. Of these patients, 152 patients had LEAD on peripheral angiography that was performed because of suspected lower‐extremity peripheral disease based on history, physical examination, and non‐invasive tests. The control group consisted of 128 patients without LEAD on peripheral angiography. Patients with LEAD were classified according to trans‐atlantic inter‐society consensus (TASC) II classification. Subsequently, patients in TASC A to B were defined as having mild to moderate peripheral artery disease, and those in TASC C to D were defined as having advanced peripheral artery disease. Thrombotic and inflammatory markers, such as the neutrophil‐to‐lymphocyte ratio (NLR), the high‐sensitivity C (hs‐C) reactive protein level, the monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, the fibrinogen to albumin ratio (FAR), and whole‐blood viscosity at high shear rate (HSR) and low shear rate (LSR), were evaluated in this population. The NLR, the monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, the FAR, and whole‐blood viscosity, both at a LSR and a HSR, were significantly higher in patients with lower‐extremity peripheral disease compared with patients without lower‐extremity peripheral disease. We determined that lower‐extremity peripheral disease severity was correlated with the NLR, monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, FAR, whole‐blood viscosity at LSR, and whole‐blood viscosity at HSR (r = 0.719, P = .004; r = 0.25, P = .008; r = 0.691, P = .002; r = 0.546, P < .001; and r = 0.448, P = .001, respectively). However hs‐C reactive protein levels were similar between patients with or without LEAD (2.47 ± 1.32 1.61 ± 0.91 P = .685). In addition, there was no correlation between the severity of LEAD and hs‐C reactive levels. In this study, we determined that the levels of inflammatory and thrombotic biomarkers are elevated in peripheral artery disease, and these levels predict disease severity.
- 22 May 2020
- Published by Wiley in International Wound Journal
- Vol. 17 (5) , 1346-1355
The association between thrombotic and inflammatory biomarkers and lower‐extremity peripheral artery disease
Lower‐extremity peripheral artery disease (LEAD) is associated with increased rates of mortality and morbidity. The aim of this study was to evaluate the associations among inflammatory and thrombotic markers and lower‐extremity peripheral disease. A total of 280 patients were enrolled in this study. Of these patients, 152 patients had LEAD on peripheral angiography that was performed because of suspected lower‐extremity peripheral disease based on history, physical examination, and non‐invasive tests. The control group consisted of 128 patients without LEAD on peripheral angiography. Patients with LEAD were classified according to trans‐atlantic inter‐society consensus (TASC) II classification. Subsequently, patients in TASC A to B were defined as having mild to moderate peripheral artery disease, and those in TASC C to D were defined as having advanced peripheral artery disease. Thrombotic and inflammatory markers, such as the neutrophil‐to‐lymphocyte ratio (NLR), the high‐sensitivity C (hs‐C) reactive protein level, the monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, the fibrinogen to albumin ratio (FAR), and whole‐blood viscosity at high shear rate (HSR) and low shear rate (LSR), were evaluated in this population. The NLR, the monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, the FAR, and whole‐blood viscosity, both at a LSR and a HSR, were significantly higher in patients with lower‐extremity peripheral disease compared with patients without lower‐extremity peripheral disease. We determined that lower‐extremity peripheral disease severity was correlated with the NLR, monocyte‐to‐high‐density lipoprotein‐cholesterol ratio, FAR, whole‐blood viscosity at LSR, and whole‐blood viscosity at HSR (r = 0.719, P = .004; r = 0.25, P = .008; r = 0.691, P = .002; r = 0.546, P < .001; and r = 0.448, P = .001, respectively). However hs‐C reactive protein levels were similar between patients with or without LEAD (2.47 ± 1.32 1.61 ± 0.91 P = .685). In addition, there was no correlation between the severity of LEAD and hs‐C reactive levels. In this study, we determined that the levels of inflammatory and thrombotic biomarkers are elevated in peripheral artery disease, and these levels predict disease severity.
- 12 March 2020
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 31 (6) , 512-517
The association between the fibrinogen-to-albumin ratio and coronary artery disease severity in patients with stable coronary artery disease
Objective: Fibrinogen-to-albumin ratio (FAR) is an inexpensive and easily measurable novel inflammatory index that has been found to be associated with atherosclerosis. In this study, we aimed to investigate the association between the FAR and coronary artery disease (CAD) severity in patients with stable CAD. Methods: In total, 356 consecutive patients with CAD were classified into three groups, those with a low Synergy between percutaneous coronary intervention and the Taxus and Cardiac Surgery Study (SYNTAX) score (≤22), those with an intermediate SYNTAX score (23≥ SYNTAX score ≤32) and those with a high SYNTAX score (>32). Results: We determined that there were significant differences in the mean age (P < 0.001), male gender (P = 0.008), serum fibrinogen (P = 0.03), low-density lipoprotein cholesterol (P < 0.001) and FAR (P < 0.001) among the SYNTAX score groups. A strong positive correlation was detected between FAR and SYNTAX score (r = 0.899; P < 0.001), and the cutoff level of FAR for high SYNTAX score was 82 (sensitivity of 82%, specificity of 88.3% and an area under the curve of 0.826). Conclusion: The novel inflammatory index, FAR, is significantly associated with the severity of CAD in patients with stable CAD.
- 12 March 2020
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 31 (6) , 512-517
The association between the fibrinogen-to-albumin ratio and coronary artery disease severity in patients with stable coronary artery disease
Objective: Fibrinogen-to-albumin ratio (FAR) is an inexpensive and easily measurable novel inflammatory index that has been found to be associated with atherosclerosis. In this study, we aimed to investigate the association between the FAR and coronary artery disease (CAD) severity in patients with stable CAD. Methods: In total, 356 consecutive patients with CAD were classified into three groups, those with a low Synergy between percutaneous coronary intervention and the Taxus and Cardiac Surgery Study (SYNTAX) score (≤22), those with an intermediate SYNTAX score (23≥ SYNTAX score ≤32) and those with a high SYNTAX score (>32). Results: We determined that there were significant differences in the mean age (P < 0.001), male gender (P = 0.008), serum fibrinogen (P = 0.03), low-density lipoprotein cholesterol (P < 0.001) and FAR (P < 0.001) among the SYNTAX score groups. A strong positive correlation was detected between FAR and SYNTAX score (r = 0.899; P < 0.001), and the cutoff level of FAR for high SYNTAX score was 82 (sensitivity of 82%, specificity of 88.3% and an area under the curve of 0.826). Conclusion: The novel inflammatory index, FAR, is significantly associated with the severity of CAD in patients with stable CAD.
- 3 February 2020
- Published by SAGE Publications in Vascular
- Vol. 28 (3) , 329-330
Screening of lower extremity artery disease
- 3 February 2020
- Published by SAGE Publications in Vascular
- Vol. 28 (3) , 329-330
Screening of lower extremity artery disease
- Open Access
- 1 January 2020
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (1) , E1-E2
An Extremely Rare Coronary Artery Anomaly: Monster Left Anterior Descending Coronary Artery
- 1 January 2020
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (1) , E1-E2
Open AccessAn Extremely Rare Coronary Artery Anomaly: Monster Left Anterior Descending Coronary Artery
- Open Access
- 1 January 2020
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 26
Blood Group Types O and Non-O Are Associated With Coronary Collateral Circulation Development
Blood group types are associated with coronary artery disease. However, data are scarce about the impact of blood group types on coronary collateral circulation. In this study, we aimed to investigate the relationship between the blood group types and coronary collateral circulation. Two hundred and twelve patients who underwent coronary angiography in our department and had a stenosis of ≥ 90% in at least one major epicardial vessel were included in our study. Collateral degree was graded according to Rentrop-Cohen classification. After grading, patients were divided into poor coronary collateral circulation (Rentrop grade 0 and 1) and good coronary collateral circulation (Rentrop 2 and 3) groups. The ABO blood type of all participants was determined. The incidence rates of O blood group type were significantly higher in the good coronary collateral group compared to the poor collateral group (37.9% vs 17.1%, P < .001). The O type blood group was an independent predictor of good coronary collateral circulation (odds ratio = 1.83, 95% confidence interval = 1.56-6.18, P = .015). Coronary collateral circulation is associated with blood group types. The O blood group predicts good coronary collateral development among patients with coronary artery disease.
- 1 January 2020
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 26
Open AccessBlood Group Types O and Non-O Are Associated With Coronary Collateral Circulation Development
Blood group types are associated with coronary artery disease. However, data are scarce about the impact of blood group types on coronary collateral circulation. In this study, we aimed to investigate the relationship between the blood group types and coronary collateral circulation. Two hundred and twelve patients who underwent coronary angiography in our department and had a stenosis of ≥ 90% in at least one major epicardial vessel were included in our study. Collateral degree was graded according to Rentrop-Cohen classification. After grading, patients were divided into poor coronary collateral circulation (Rentrop grade 0 and 1) and good coronary collateral circulation (Rentrop 2 and 3) groups. The ABO blood type of all participants was determined. The incidence rates of O blood group type were significantly higher in the good coronary collateral group compared to the poor collateral group (37.9% vs 17.1%, P < .001). The O type blood group was an independent predictor of good coronary collateral circulation (odds ratio = 1.83, 95% confidence interval = 1.56-6.18, P = .015). Coronary collateral circulation is associated with blood group types. The O blood group predicts good coronary collateral development among patients with coronary artery disease.